Prelude Therapeutics (PRLD) Current Leases (2019 - 2026)

Prelude Therapeutics has reported Current Leases for 7 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Current Leases rose 6.19% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 6.19% YoY) and the FY2025 annual result came in at $2.7 million, up 1219.23% from the prior year.
• Current Leases rose to $2.8 million in Q1 2026 per PRLD's latest filing, from $2.7 million in the prior quarter.
• Over five years, Current Leases peaked at $2.8 million in Q1 2026 and troughed at $208000.0 in Q4 2024.
• A 5-year average of $1.8 million and a median of $1.8 million in 2022 frame the typical range for Current Leases.
• The sharpest annual moves came in 2024 and 2025: Current Leases sank 85.96% in 2024, then surged 1219.23% in 2025.
• Over 5 years, Current Leases stood at $1.8 million in 2022, then slipped by 19.16% to $1.5 million in 2023, then tumbled by 85.96% to $208000.0 in 2024, then soared by 1219.23% to $2.7 million in 2025, then climbed by 0.62% to $2.8 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $2.8 million, $2.7 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.